Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Joseph Baroldi reported an open-market sale of company stock. On this Form 4, the EVP and Chief Business Officer sold 1,626 shares of Ionis Pharmaceuticals common stock on April 28, 2026 at a weighted average price of $71.7877 per share in an open-market transaction.

The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by Baroldi on November 25, 2025. After the transaction, he directly owned 44,909 shares of common stock. A separate holding entry shows 4,347 shares of common stock held indirectly by his spouse.

Insider Trade Summary 10b5-1

Net Seller: 1,626 shares ($116,727)

Net Sell 2 txns

Insider Baroldi Joseph

Role EVP, Chief Business Officer

Sold 1,626 shs ($117K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,626	$71.7877	$117K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 44,909 shares (Direct, null); Common Stock — 4,347 shares (Indirect, by Spouse)

Footnotes (1)

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.67 to $71.825 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Key Figures

Shares sold: 1,626 shares Weighted average sale price: $71.7877 per share Direct holdings after sale: 44,909 shares +1 more

4 metrics

Shares sold 1,626 shares Open-market sale on April 28, 2026

Weighted average sale price $71.7877 per share Common stock sale on April 28, 2026

Direct holdings after sale 44,909 shares Common stock directly owned following transaction

Indirect spouse holdings 4,347 shares Common stock held indirectly by spouse as of April 28, 2026

Key Terms

Rule 10b5-1 Trading Plan, weighted average price, open-market sale, indirect

4 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect financial

""ownership_type": "indirect""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baroldi Joseph

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/28/2026		S		1,626(1)	D	$71.7877(2)	44,909	D
Common Stock								4,347	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.67 to $71.825 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Joseph T. Baroldi	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ionis (IONS) executive Joseph Baroldi report?

Joseph Baroldi reported an open-market sale of Ionis common stock. He sold 1,626 shares on April 28, 2026, as disclosed in a Form 4. The filing classifies this as a non-derivative transaction in Ionis Pharmaceuticals common stock.

How many Ionis (IONS) shares did Joseph Baroldi sell and at what price?

Baroldi sold 1,626 shares of Ionis common stock. The filing reports a weighted average sale price of $71.7877 per share, with multiple trades executed in a price range from $71.67 to $71.825, according to the footnote disclosure.

How many Ionis (IONS) shares does Joseph Baroldi hold after this Form 4 transaction?

After the reported sale, Baroldi directly held 44,909 shares of Ionis common stock. The Form 4 also shows an additional 4,347 shares held indirectly, noted as owned “by Spouse,” reflecting indirect beneficial ownership separate from his direct holdings.

Was Joseph Baroldi’s Ionis (IONS) stock sale made under a Rule 10b5-1 plan?

Yes. A footnote states the shares were sold pursuant to a Rule 10b5-1 Trading Plan adopted by Baroldi on November 25, 2025. This indicates the sales followed instructions established in that pre-adopted trading plan.

What does the Form 4 reveal about indirect Ionis (IONS) holdings for Joseph Baroldi?

The Form 4 includes a holding entry for 4,347 Ionis common shares reported as owned indirectly “by Spouse.” This line is classified as a holding, not a buy or sell transaction, and reflects indirect ownership separate from Baroldi’s direct position.